F-1: Living Homeopathy International Files for Nasdaq IPO Amidst Declining Revenue and Net Loss

Living Homeopathy International Ltd., a Hong Kong-based homeopathy service provider, has filed an F-1 registration statement for an initial public offering of 1,250,000 Class A ordinary shares on the Nasdaq Capital Market, seeking to raise approximately $4.13 million in net proceeds despite recent declines in revenue and a shift to net loss in the most recent interim period.

Summary

• Living Homeopathy International Ltd. is a Cayman Islands holding company with primary operations in Hong Kong through its subsidiary, Living Homeopathy Limited, providing homeopathy services and products.
• The company is seeking to raise capital through an initial public offering of 1,250,000 Class A ordinary shares, with an estimated price range of $4.0 to $6.0 per share, aiming for approximately $4.13 million in net proceeds.
• Proceeds from the offering are planned to be allocated 40% for advertising, 30% for market and product development and marketing, and 30% for working capital and general corporate purposes.
• The company reported a decrease in total net revenue by 7.1% from $9,162,896 in fiscal year 2023 to $8,510,216 in fiscal year 2024.
• Net income significantly declined by 33.3% from $1,129,504 in fiscal year 2023 to $753,429 in fiscal year 2024.
• For the six months ended September 30, 2024, the company reported a net loss of $33,934, a substantial decline from a net income of $520,092 in the same period of 2023.
• Operating income for the six months ended September 30, 2024, plummeted by 95.2% to $29,926 from $627,646 in the prior comparable period.
• The company's business model includes a 'mentor-mentee program' for sales and marketing, which involves product discounts and sales commissions tied to product sales, and a nominal one-off membership fee of HKD500 ($63.9).
• The controlling shareholder, Mr. Ka Lun To, through his holding company, will retain approximately 49.43% of the total voting power post-IPO, and together with another Class B shareholder, will control 91.09% of total voting power.
• A significant related party transaction occurred on August 13, 2024, involving the transfer of land and building with a net carrying amount of $1,954,119 to Mr. To, discharging $2,153,057 in bank borrowings and resulting in a net increase of $38,183 in amount due to shareholder.

Sentiment

Score: 3

Explanation: The company is a market leader in a growing industry, but recent financial performance shows significant declines, including a net loss in the most recent interim period. There are substantial regulatory and operational risks, particularly concerning PRC government intervention, the nature of homeopathy, and the mentor-mentee program's potential classification as a pyramid scheme. The high concentration of voting power and related party transactions also present concerns.

Positives

• Living Homeopathy is ranked first in the Hong Kong homeopathy market with approximately 41.3% market share in terms of product sales revenue in 2023, indicating strong market influence.
• The company offers a diversified product portfolio including homeopathic remedies, co-remedies, classical flower remedies, personal care products, and water filters, catering to a broad customer base.
• An established quality control practice is in place, including supplier selection and product quality checks, with key products obtaining STC Certified Mark.
• The company maintains long-term business relationships with the majority of its top 5 suppliers, some for over a decade, providing stable supply and reducing negotiation costs.
• The management team and practitioners are experienced, with 636 practitioners holding Homeopathy First Aid Certificates and 71 being nutritional therapy practitioners, enhancing service quality.
• The company plans to diversify sales channels by developing an online flagship store on Tmall Global to reach consumers in mainland China, indicating a growth strategy.
• Net cash generated from operating activities for the six months ended September 30, 2024, increased to $362,130 from $302,872 in the prior comparable period, despite a net loss.

Negatives

• Total net revenue decreased by 7.1% for the year ended March 31, 2024, and by 7.4% for the six months ended September 30, 2024, primarily due to decreased sales of healthcare products.
• Net income declined by 33.3% for the year ended March 31, 2024, and the company reported a net loss of $33,934 for the six months ended September 30, 2024, compared to a net income of $520,092 in the prior comparable period.
• Income from operations significantly decreased by 28.4% for the year ended March 31, 2024, and by 95.2% for the six months ended September 30, 2024.
• The company's mentor-mentee program, a key sales and marketing network, faces risks of being deemed a pyramid scheme under Hong Kong law, which could materially and adversely affect the business.
• The company has been subject to negative publicity, including a case of silver poisoning allegedly involving its 'LIVING Colloidal Silver' product, leading to termination of sales for human use and potential reputational damage.
• The company does not have written contracts with any of its suppliers, which reduces procurement predictability and could lead to order cancellations or modifications on short notice without penalty.
• The company has substantial supplier concentration, with a limited number of suppliers accounting for a significant portion of total purchases and accounts payable.
• The company does not maintain business interruption insurance or product liability insurance, exposing it to significant costs and business disruption from unforeseen events or product-related claims.
• The company's effective income tax rate for the six months ended September 30, 2024, was 368.2%, significantly higher than 14.1% in the prior comparable period, mainly due to an increase in deferred income tax expense from transferring properties to the controlling shareholder.

Risks

• The PRC government may intervene or influence Hong Kong operations and exert more control over overseas offerings and foreign investment, potentially limiting or hindering the company's ability to operate or offer securities.
• Uncertainties exist regarding future requirements for approvals from mainland China and Hong Kong authorities for listing securities on U.S. exchanges and offering securities.
• The company may be subject to delisting from Nasdaq under the Holding Foreign Companies Accountable Act (HFCA Act) if its auditor is not subject to PCAOB inspections for two consecutive years, despite its current U.S.-based auditor being inspected.
• The homeopathy industry is competitive and rapidly evolving, making it difficult to evaluate prospects and manage growth effectively.
• Unfavorable publicity or consumer acceptance of homeopathy products could reduce sales and damage reputation, as seen with the 'LIVING Colloidal Silver' incident.
• Potential product liability, false marketing, or other consumer claims could lead to substantial liabilities and regulatory penalties.
• Employees or participants in the mentor-mentee program may engage in improper marketing or promotion, leading to enforcement actions.
• The mentor-mentee program's sustainability relies on strict compliance with internal codes of conduct and relevant laws, with a risk of being classified as a pyramid scheme.
• Product recalls could incur significant and unexpected costs and damage reputation.
• The company may require substantial additional funding in the future, and there is no assurance that additional financing will be available on reasonable terms.
• Increases in labor costs in Hong Kong and non-compliance with employment and labor protection laws may adversely affect business and results of operations.
• Failure to manage and expand supplier relationships or procure products on favorable terms could harm business and growth prospects.
• Lack of written contracts with suppliers reduces procurement predictability and exposes the company to short-notice cancellations or modifications without penalty.
• The business depends on the continued efforts of senior management, and their inability or unwillingness to continue could severely disrupt operations.
• Directors, management, and shareholders may be subject to negative publicity, claims, or legal proceedings.
• Reliance on proprietary information, such as trade secrets and know-how, carries risks of unauthorized disclosure or independent development by competitors.
• The company may be accused of infringing intellectual property rights of others.
• Proper functioning of information technology systems is essential, and failure to maintain satisfactory performance or protect data could harm reputation and operations.
• Lack of insurance coverage for business interruption or product liability could expose the company to significant costs.
• Financial and operating performance may be adversely affected by epidemics, natural disasters, and other catastrophes.
• Concentrated voting power by directors, officers, and Class B shareholders (91.09% post-IPO) may limit the influence of other shareholders.
• Shareholders may face difficulties protecting their interests and enforcing rights through U.S. courts due to incorporation under Cayman Islands law.
• The company relies on dividends and other distributions from its Hong Kong subsidiary for cash and financing requirements, which could be limited.
• Lack of effective internal controls over financial reporting may affect the ability to accurately report financial results or prevent fraud.
• The company will incur increased costs as a public company, particularly after ceasing to qualify as an emerging growth company.
• The Class A Ordinary Shares may be thinly traded and subject to extreme price volatility unrelated to operating performance.
• New investors will experience immediate and substantial dilution of approximately $4.44 per Ordinary Share.
• The company does not expect to pay dividends in the foreseeable future, requiring investors to rely on price appreciation for returns.
• Substantial future sales or perceived potential sales of Class A Ordinary Shares could cause the price to decline.
• The company may be classified as a passive foreign investment company (PFIC), which could result in adverse U.S. federal income tax consequences to U.S. Holders.

Future Outlook

The company plans to diversify its sales channels by developing an online flagship store on Tmall Global to sell brand-name goods directly to consumers in mainland China, with key products expected to be homeopathic co-remedies. It also intends to promote market regularization and standardization in the homeopathy markets of Hong Kong and mainland China by working with regional institutes and medical schools. The company currently intends to retain all available funds and future earnings for business operation and expansion and does not anticipate paying any cash dividends to U.S. investors in the foreseeable future following the offering.

Management Comments

• "We are a Hong Kong-based homeopathy service provider committed to providing customers with access to quality homeopathy resources as alternative treatment to enhance holistic health and wellness."
• "We believe that we may leverage this established market share to enhance the market influence of our brand name to further attract customer attention and increase our sales."
• "We have established an extensive mentor and mentee network."
• "We structure our mentor-mentee program and set up mentor-mentee program related code of conduct to prevent the mentor-mentee program from becoming a pyramid structure as pyramid schemes are prohibited in Hong Kong."
• "We believe the mentor-mentee network benefits customer education to enhance market awareness of homeopathy and our homeopathic products as alternative treatment to conventional medicines with a focus on holistic physical and emotional therapy."
• "We believe that our existing resources, including cash generated from operations, will be sufficient to meet our working capital requirement for our current operating and capital expenditure needs and obligations over the next twelve months."
• "In order to fully implement its business plan and sustain continued growth, the Company may also need to raise capital from equity and debt financings."

Industry Context

The Traditional and Complementary Medicine (T&CM) market in Hong Kong has shown robust growth, expanding from $176 million in 2019 to $309.4 million in 2023 (CAGR of 15.1%), with projections to reach $1,299.1 million by 2029 (CAGR of 25.3% from 2024-2028). The homeopathy market specifically grew from $16.6 million in 2019 to $20 million in 2023 (CAGR of 4.8%) and is projected to accelerate to a 12.0% CAGR from 2024-2028, reaching $42.9 million by 2029. Growth drivers include rising chronic diseases, an increasing aging population in Hong Kong (21.4% aged 65+ in 2023), and enhancing cultural acceptance of T&CM. Future trends include increased regulation and standardization, rising investment in research and clinical validation, and the adoption of digital health and telemedicine. Entry barriers are significant due to capital requirements, brand reputation, difficulty in attracting experienced professionals, and regulatory compliance.

Comparison to Industry Standards

• Living Homeopathy holds a leading position in the Hong Kong homeopathy market, ranking first with approximately 41.3% market share in terms of homeopathy product sales revenue in 2023, according to Frost & Sullivan, indicating a strong competitive standing within its niche.
• The company's gross margin of 75.0% for FY2024 and 74.9% for FY2023, and 74.9% for 6M Sep 2024 and 75.7% for 6M Sep 2023, suggests a healthy profitability on its products, which is a positive indicator compared to general retail or manufacturing industry standards.
• The decline in revenue and net income, particularly the shift to a net loss in the most recent interim period, contrasts with the overall projected growth of the broader T&CM market (25.3% CAGR) and the homeopathy market (12.0% CAGR) in Hong Kong, suggesting the company is currently underperforming relative to market trends.
• The company's reliance on a limited number of suppliers and lack of written contracts with them is a deviation from standard supply chain risk management practices, which typically involve diversified suppliers and formal agreements to ensure stability and mitigate risks.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any legal proceedings that, in the opinion of management, would have a material adverse effect on its business, financial condition, operating results, or cash flows.

Related Party Transactions

• The company sold healthcare, personal care, and water filter products to Living Homeopathy Limited (Macau), an entity controlled by Mr. To, generating revenue of $368,969 in FY2024 and $422,049 in FY2023.
• The company purchased certain healthcare products from Living Homeopathy Limited (Macau), totaling $456,773 in FY2024 and $562,759 in FY2023.
• Living Homeopathy Hong Kong leased an office premise from Silver Link Limited, an entity controlled by Mr. To, incurring lease expenses of $184,036 in FY2024 and $183,700 in FY2023.
• An amount due to Mr. To of $76,996 as of March 31, 2023, was settled by December 31, 2023.
• On August 13, 2024, Living HK transferred ownership of land and building (net carrying amount $1,954,119) to Mr. To, discharging $2,153,057 in bank borrowings, resulting in a net increase of $38,183 in the amount due to shareholder (Mr. To).
• As of September 30, 2024, amounts due to related parties included $92,292 to Mr. To and $671,302 to Ms. Hung (a shareholder).

Stakeholder Impact

• Shareholders: New investors will experience significant dilution from the IPO. The dual-class share structure concentrates voting power with existing controlling shareholders, limiting influence for public Class A shareholders. No dividends are expected in the foreseeable future, requiring reliance on share price appreciation.
• Employees: The company's success depends on attracting and retaining qualified employees. Changes in labor costs in Hong Kong could impact profitability. The mentor-mentee program provides sales commissions and product discounts, impacting participants' earnings.
• Customers: The company's business relies on consumer awareness and acceptance of homeopathy, which can be influenced by scientific findings and publicity. Product liability claims or negative publicity could reduce sales and consumer confidence.
• Suppliers: The company's reliance on a limited number of suppliers and lack of written contracts could lead to supply disruptions or increased procurement costs, potentially affecting product availability and pricing.
• Regulatory Authorities: The company faces significant regulatory scrutiny in Hong Kong and potential intervention from the PRC government, which could impact operations, financial condition, and ability to offer securities.

Next Steps

• The company will proceed with the initial public offering contingent upon final approval from Nasdaq for the listing of its Class A Ordinary Shares on the Nasdaq Capital Market.
• Net proceeds from the offering will be used for advertising planning (40%), market and product development and marketing (30%), and working capital and general corporate purposes (30%).
• The company plans to diversify sales channels by developing its online flagship store on Tmall Global for mainland China consumers.
• The company is committed to promoting market regularization and standardization of the homeopathy market in Hong Kong and mainland China by working with regional institutes and medical schools.
• The company will incur increased costs as a public company and will need to implement and maintain effective internal controls over financial reporting.

Key Dates

Keywords

Homeopathy, Healthcare products, Personal care products, Water filters, Hong Kong, IPO, Nasdaq Capital Market, SEC filing, F-1 registration, Alternative medicine, Wellness products, Homeopathic remedies, Market share, Dual-class shares, Related party transactions, Regulatory risk, China risk, Cayman Islands company, Emerging growth company, Foreign private issuer